BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 38281880)

  • 21. Tumor Microenvironment in Oral Cancer Following Neoadjuvant Pembrolizumab: Preliminary Analysis of the Histopathologic Findings.
    Dobriyan A; Gluck I; Alon E; Barshack I; Yahalom R; Vered M
    Front Oral Health; 2021; 2():653104. PubMed ID: 35048002
    [No Abstract]   [Full Text] [Related]  

  • 22. Characterisation of tumour-immune phenotypes and PD-L1 positivity in squamous bladder cancer.
    Jung M; Rose M; Knuechel R; Loeffler C; Muti H; Kather JN; Gaisa NT;
    BMC Cancer; 2023 Feb; 23(1):113. PubMed ID: 36726072
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Association of HIV Status With Local Immune Response to Anal Squamous Cell Carcinoma: Implications for Immunotherapy.
    Yanik EL; Kaunitz GJ; Cottrell TR; Succaria F; McMiller TL; Ascierto ML; Esandrio J; Xu H; Ogurtsova A; Cornish T; Lipson EJ; Topalian SL; Engels EA; Taube JM
    JAMA Oncol; 2017 Jul; 3(7):974-978. PubMed ID: 28334399
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prognosis significance of indoleamine 2, 3-dioxygenase, programmed death ligand-1 and tumor-infiltrating immune cells in microenvironment of breast cancer.
    Wei L; Wu N; Wei F; Li F; Zhang Y; Liu J; Ren X
    Int Immunopharmacol; 2020 Jul; 84():106506. PubMed ID: 32330866
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Multi-perspective comparison of the immune microenvironment of primary colorectal cancer and liver metastases.
    He Y; Han Y; Fan AH; Li D; Wang B; Ji K; Wang X; Zhao X; Lu Y
    J Transl Med; 2022 Oct; 20(1):454. PubMed ID: 36195882
    [TBL] [Abstract][Full Text] [Related]  

  • 26. PD-L1 expression correlates with tumor-infiltrating lymphocytes and better prognosis in patients with HPV-negative head and neck squamous cell carcinomas.
    Sanchez-Canteli M; Granda-Díaz R; Del Rio-Ibisate N; Allonca E; López-Alvarez F; Agorreta J; Garmendia I; Montuenga LM; García-Pedrero JM; Rodrigo JP
    Cancer Immunol Immunother; 2020 Oct; 69(10):2089-2100. PubMed ID: 32448984
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immunohistochemical Analysis of Foxp3
    Stasikowska-Kanicka O; Wągrowska-Danilewicz M; Danilewicz M
    Pathol Oncol Res; 2018 Jul; 24(3):497-505. PubMed ID: 28669079
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Tumor-associated macrophage infiltration is highly associated with PD-L1 expression in gastric adenocarcinoma.
    Harada K; Dong X; Estrella JS; Correa AM; Xu Y; Hofstetter WL; Sudo K; Onodera H; Suzuki K; Suzuki A; Johnson RL; Wang Z; Song S; Ajani JA
    Gastric Cancer; 2018 Jan; 21(1):31-40. PubMed ID: 28801853
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Epithelial PD-L1 expression at tumor front predicts overall survival in a cohort of oral squamous cell carcinomas from Sudan.
    Gaafar NM; Osman TA; Elsheikh M; Ahmed IA; Dongre H; Fromreide S; Suleiman AM; Johannessen AC; Nginamau ES; Costea DE
    Clin Exp Dent Res; 2022 Dec; 8(6):1467-1477. PubMed ID: 36177667
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prognostic implications of preoperative systemic inflammatory markers in oral squamous cell carcinoma, and correlations with the local immune tumor microenvironment.
    Ruiz-Ranz M; Lequerica-Fernández P; Rodríguez-Santamarta T; Suárez-Sánchez FJ; López-Pintor RM; García-Pedrero JM; de Vicente JC
    Front Immunol; 2022; 13():941351. PubMed ID: 35958590
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparison of three PD-L1 immunohistochemical assays in head and neck squamous cell carcinoma (HNSCC).
    de Ruiter EJ; Mulder FJ; Koomen BM; Speel EJ; van den Hout MFCM; de Roest RH; Bloemena E; Devriese LA; Willems SM
    Mod Pathol; 2021 Jun; 34(6):1125-1132. PubMed ID: 32759978
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Malignant pleural mesothelioma immune microenvironment and checkpoint expression: correlation with clinical-pathological features and intratumor heterogeneity over time.
    Pasello G; Zago G; Lunardi F; Urso L; Kern I; Vlacic G; Grosso F; Mencoboni M; Ceresoli GL; Schiavon M; Pezzuto F; Pavan A; Vuljan SE; Del Bianco P; Conte P; Rea F; Calabrese F
    Ann Oncol; 2018 May; 29(5):1258-1265. PubMed ID: 29514216
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The Prognostic Value of Immune Factors in the Tumor Microenvironment of Penile Squamous Cell Carcinoma.
    Ottenhof SR; Djajadiningrat RS; Thygesen HH; Jakobs PJ; Jóźwiak K; Heeren AM; de Jong J; Sanders J; Horenblas S; Jordanova ES
    Front Immunol; 2018; 9():1253. PubMed ID: 29942303
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Spatial and Quantitative Analysis of Tumor-Associated Macrophages: Intratumoral CD163-/PD-L1+ TAMs as a Marker of Favorable Clinical Outcomes in Triple-Negative Breast Cancer.
    Shinohara H; Kobayashi M; Hayashi K; Nogawa D; Asakawa A; Ohata Y; Kubota K; Takahashi H; Yamada M; Tokunaga M; Kinugasa Y; Oda G; Nakagawa T; Onishi I; Kinowaki Y; Kurata M; Ohashi K; Kitagawa M; Yamamoto K
    Int J Mol Sci; 2022 Oct; 23(21):. PubMed ID: 36362023
    [TBL] [Abstract][Full Text] [Related]  

  • 35. FOXP3-based immune risk model for recurrence prediction in small-cell lung cancer at stages I-III.
    Jiang M; Wu C; Zhang L; Sun C; Wang H; Xu Y; Sun H; Zhu J; Zhao W; Fang Q; Yu J; Chen P; Wu S; Zheng Z; He Y; Zhou C
    J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 34006632
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The preliminary exploration of immune microenvironment in oral leukoplakia concomitant with oral submucosal fibrosis: A comparative immunohistochemical study.
    Cai X; Zhang J; Peng Y; Yao Z; Huang J; Tang Q; Bai J; Yan J; Li L; Zhang H; Li T
    J Oral Pathol Med; 2023 Aug; 52(7):666-672. PubMed ID: 37084341
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical and Biological Significance of PD-L1 Expression Within the Tumor Microenvironment of Oral Squamous Cell Carcinoma.
    Takahashi H; Sakakura K; Arisaka Y; Tokue A; Kaira K; Tada H; Higuchi T; Okamoto A; Tsushima Y; Chikamatsu K
    Anticancer Res; 2019 Jun; 39(6):3039-3046. PubMed ID: 31177146
    [TBL] [Abstract][Full Text] [Related]  

  • 38. PD-L1 expression patterns in oral cancer as an integrated approach for further prognostic classification.
    Miranda-Galvis M; Rumayor Piña A; Sales de Sá R; Almeida Leite A; Agustin Vargas P; Calsavara VF; Lópes Pinto CA; Teng Y; Kowalski LP
    Oral Dis; 2021 Oct; 27(7):1699-1710. PubMed ID: 33169454
    [TBL] [Abstract][Full Text] [Related]  

  • 39. PD-L1 expression and immune cells in anaplastic carcinoma and poorly differentiated carcinoma of the human thyroid gland: A retrospective study.
    Cameselle-García S; Abdulkader-Sande S; Sánchez-Ares M; Rodríguez-Carnero G; Garcia-Gómez J; Gude-Sampedro F; Abdulkader-Nallib I; Cameselle-Teijeiro JM
    Oncol Lett; 2021 Jul; 22(1):553. PubMed ID: 34093774
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Single-cell RNA sequencing reveals compartmental remodeling of tumor-infiltrating immune cells induced by anti-CD47 targeting in pancreatic cancer.
    Pan Y; Lu F; Fei Q; Yu X; Xiong P; Yu X; Dang Y; Hou Z; Lin W; Lin X; Zhang Z; Pan M; Huang H
    J Hematol Oncol; 2019 Nov; 12(1):124. PubMed ID: 31771616
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.